Gian Life Care Ltd.
Snapshot View

17.60 -0.90 ▼-4.9%

27 May 2022, 04:01:00 PM
Volume: 6,600

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Compare with Industry peers
Website http://www.gianpathlabs.com
Market Cap 18.20 Cr.
Enterprise Value(EV) 16.70 Cr. 2021-03
Financial Indicators
Earnings per share (EPS) 1.95 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 9.02 Trailing Twelve Months Ending 2021-03
Industry PE 39.89 Trailing Twelve Months Ending 2021-03
Book Value / Share 17.62 Trailing Twelve Months Ending 2021-03
Price to Book Value 1.00 Calculated using Price: 17.60
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 1.03 Cr. 10,341,527 Shares
FaceValue 10
Company Profile

Gian Life Care was incorporated on November 06, 2018, under the provisions of the Companies Act, 2013 by Registrar of Companies, Kanpur. On March 01, 2019 the company took over the entire running business of Gian Pathology and X-Rays, a proprietorship concern of the promoter Arun Kumar Gupta with a view to provide diagnostic and related healthcare tests and services.

Business area of the Company:

The company is engaged in the business of providing diagnostic and related healthcare services. The company provides a wide range of diagnostic tests and services like patient diagnosis services, prevention, and wellness diagnosis services to patients and healthcare providers. The company caters to individual patients, hospitals, corporates and other healthcare providers. The company offers various tests including biochemistry, clinical pathology, coagulation, cytogenetics, cytology, hematology, histopathology, immunoassay, microbiology, molecular biology, and radiology services.

Key Events and Milestones:

  • 2018: Incorporation of the company in the name of ‘Gian Life Care Limited’
  • 2019: Acquired the running business along with substantial assets and liabilities of Gian Pathology and X rays, proprietorship concern of the Promoter.

 

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-4.86%
1 Week
-16.39%
1 Month
-38.46%
3 Month
-60.27%
6 Month
-62.77%
1 Year
+77.96%
2 Year
+193.33%
5 Year
10 Year
3 years 2019-03 2020-03 2021-03
Return on Equity (%) 90.94 29.34 23.33
Return on Capital Employed (%) 12.26 42.76 35.91
Return on Assets (%) 1.28 11.16 14.49

Balance Sheet View Details

Particulars 3 years 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Shh. Funds 0 8 10
Non Curr. Liab. 1 1 1
Curr. Liab. 7 4 5
Minority Int.
Equity & Liab. 8 12 15
Non Curr. Assets 4 8 9
Curr. Assets 3 4 6
Misc. Exp. not W/O
Total Assets 8 12 15

Profit Loss View Details

Particulars 3 years 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 1 8 10
Other Income 0 0
Total Income 1 8 11
Total Expenditure 0 -5 -7
PBIDT 0 2 4
Interest 0 -1 -1
Depreciation 0 0 0
Taxation 0 0 -1
Exceptional Items
PAT 0 1 2
Adjusted EPS 0 1 2

Cash Flow View Details

Particulars 3 years 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 3 2 3
Cash Fr. Inv. -3 -4 -1
Cash Fr. Finan. 1 3 0
Net Change 1 0 1
Cash & Cash Eqvt 1 1 3

Shareholding Pattern View Details

5 Qtrs 2020-03 (%) 2020-09 (%) 2021-03 (%) 2021-09 (%) 2022-03 (%)
Promoter 69.87 69.87 69.87 69.87 64.95
Public 30.13 30.13 30.13 30.13 35.05
Depository Receipts 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Tue, 24 May 2022
Board Meeting Intimation for Intimation Of Board Meeting To Consider And Approve Audited Standalone And Consolidated Financial Results Of The Company For The Quarter/ Half Year And Year Ended 31St March 2022
Gian Life Care Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 inter alia to consider and approve Pursuant to Regulation 29 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended from time to time we wish to intimate that the meeting of Board of Directors of the Company is scheduled to be held on Monday the 30th day of May 2022:-1. To interallia consider and approve Audited Standalone and Consolidated Financial results of the Company for the quarter/ half year and year ended 31st March 2022.2. Any other business which forms part of the Agenda Paper.Kindly take the same on record.Yours faithfully For GIAN LIFE CARE LIMITED
Fri, 06 May 2022
Announcement under Regulation 30 (LODR)-Resignation of Chief Executive Officer (CEO)
Dear Sir/Maam Subject: Intimation of Resignation of Chief Executive Officer under Regulation 30 (LODR)Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to intimate that the Company has received a letter from Mr. Sanjay Bhargava about his resignation from the post of Chief Executive Officer of the Company.
Fri, 29 Apr 2022
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Dear Sir/Madam We enclose herewith the Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for period ended March 31 2022 for your information and record.Thanking You Yours faithfully For GIAN LIFE CARE LIMITED

Technical Scans View Details

Fri, 27 May 2022
High Delivery Percentage High Delivery Percentage
Opening at High Opening at High
Opening at Low Opening at Low
Closing Below Previous Low Closing Below Previous Low
Closing Below Previous Low for 3 days Closing Below Previous Low for 3 days

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 216,539.98 902.50 +0.2%
Divi's Laboratories Ltd. 93,297.61 3,514.45 +1.9%
Cipla Ltd. 77,954.36 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. 73,094.23 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. 55,313.96 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. 49,744.83 2,939.85 +1.3%
Gland Pharma Ltd. 47,677.82 2,897.00 +1.5%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 33.60 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2022-03 31.51 3,514.45 +1.9%
Cipla Ltd. Consolidated 2022-03 30.97 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 33.49 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 52.40 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 64.02 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2022-03 39.35 2,897.00 +1.5%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.19 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2022-03 7.95 3,514.45 +1.9%
Cipla Ltd. Consolidated 2022-03 3.74 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.80 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 9.81 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8.36 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2022-03 6.66 2,897.00 +1.5%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 3,514.45 +1.9%
Cipla Ltd. Consolidated 2021-03 0.10 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 0.84 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2021-03 0.00 2,897.00 +1.5%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,514.45 +1.9%
Cipla Ltd. Consolidated 2021-03 14.13 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,897.00 +1.5%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,514.45 +1.9%
Cipla Ltd. Consolidated 2021-03 14.13 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,897.00 +1.5%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 3,514.45 +1.9%
Cipla Ltd. Consolidated 2021-03 19,159.59 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 8,004.83 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 2,897.00 +1.5%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 3,514.45 +1.9%
Cipla Ltd. Consolidated 2021-03 2,401.30 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 1,251.88 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2021-03 996.96 2,897.00 +1.5%